Single-dose quinidine treatment inhibits metoprolol oxidation in extensive metabolizers
- 1 January 1986
- journal article
- Published by Springer Nature in European Journal of Clinical Pharmacology
- Vol. 29 (6), 739-741
- https://doi.org/10.1007/bf00615971
Abstract
No abstract availableThis publication has 15 references indexed in Scilit:
- Characterization of a common genetic defect of cytochrome P-450 function (debrisoquine-sparteine type polymorphism) — Increased michaelis constant (km) and loss of stereoselectivity of bufuralol 1′-hydroxylation in poor metabolizersBiochemical and Biophysical Research Communications, 1984
- Debrisoquine-type polymorphism of drug oxidation: purification from human liver of a cytochrome P450 isozyme with high activity for bufuralol hydroxylationFEBS Letters, 1984
- OXIDATION POLYMORPHISM HAS CLINICAL RELEVANCEThe Lancet, 1984
- Quinidine-induced rise in ajmaline plasma concentrationJournal of Pharmacy and Pharmacology, 1984
- Competitive inhibition of sparteine oxidation in human liver by β-adrenoceptor antagonists and other cardiovascular drugsLife Sciences, 1984
- Childhood leukaemia: a relationship between intracellular 6‐ mercaptopurine metabolites and neutropenia.British Journal of Clinical Pharmacology, 1983
- Defective metabolism of metoprolol in poor hydroxylators of debrisoquine.British Journal of Clinical Pharmacology, 1982
- Nortriptyline and antipyrine clearance in relation to debrisoquine hydroxylation in manLife Sciences, 1980
- A family and population study of the genetic polymorphism of debrisoquine oxidation in a white British population.Journal of Medical Genetics, 1980
- POLYMORPHIC HYDROXYLATION OF DEBRISOQUINE IN MANThe Lancet, 1977